DEBRA COLEMAN: Open Payments
NPI 1376378034 · COUNCIL BLUFFS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$450 in 24 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $34 · 2025 $450
Food & beverage: $450
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $78 |
| Novo Nordisk Inc | 4 | $73 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| ABBVIE INC. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
Products named: MOUNJARO, GEMTESA, REXULTI, VRAYLAR, Rybelsus, GVOKE HYPOPEN, Veozah, INSPIRE.
Industry payments across IA — which companies pay providers there.
